GENNIEFY
Market News
Latest financial news and analysis from global markets
GILD
Gilead Sciences buys autoimmune biotech Ouro Medicines for $2.2bn
Gilead Sciences is buying autoimmune disease biotech Ouro Medicines for nearly $2.2bn as the drugmaker kick-starts a dealmaking spree emboldened...
XAU/USD
Assessing Gold.com (GOLD) Valuation After Director Share Sale And Gold Price Pullback
Director share sale and gold price pullback weigh on Gold.com Gold.com (GOLD) has come into focus after director Jeffrey D. Benjamin sold 27,618 shares for about US$1.4 million, as the stock reacted to a sharp pullback in global gold prices. See our latest analysis for Gold.com. Despite the recent pullback linked to weaker gold prices and the director sale, Gold.com’s 30.1% 3 month share price return and 59.6% 1 year total shareholder return suggest momentum has been building rather than...
PFE
Pfizer Lyme Vaccine Data Adds New Angle To Vaccine Portfolio Story
Pfizer and Valneva reported Phase 3 results for their Lyme disease vaccine candidate, with over 70% efficacy. The trial did not meet its primary endpoint, mainly due to lower than expected Lyme disease incidence during the study. Despite this, the companies view the data as clinically meaningful and plan to move ahead with regulatory submissions. For investors watching NYSE:PFE, this vaccine update adds a fresh piece to the story around Pfizer beyond its established franchises. The stock...
BTCUSDT
A Look At IREN (IREN) Valuation As AI And Bitcoin Sentiment Lift Investor Interest
IREN (NasdaqGS:IREN) has been in focus as investors react to rising interest in GPU based cloud services for AI and a recent Bitcoin rebound linked to easing US Iran tensions, which has lifted crypto related sentiment. See our latest analysis for IREN. Despite the recent Bitcoin rebound and interest in GPU based cloud services, IREN’s short term share price performance has been mixed, with a 7 day share price return of a 6.2% decline and a 30 day share price return of a 5.5% gain. The 1 year...
MSFT
Musk’s Terafab And Lace’s Atom Beams Test ASML’s Long-Term Edge
Elon Musk is reportedly planning a large scale semiconductor fabrication project called Terafab that could require extensive access to leading edge lithography tools. Microsoft backed startup Lace is developing helium atom beam lithography, targeting chip features smaller than those produced by current equipment. These developments arrive at a time when ASML Holding (ENXTAM:ASML) maintains a central role in advanced chip manufacturing through its EUV systems. For investors tracking...
INTC
S&P 500 Update This Week: 2 Signals to Watch After Signet Jewelers' Earnings
Signet investors have good reason for optimism amid uncertainty.
NVDA
S&P 500 Update This Week: 2 Signals to Watch After Signet Jewelers' Earnings
Signet investors have good reason for optimism amid uncertainty.
GILD
Gilead to buy Ouro Medicines for up to $2.2 billion
Investing.com -- Gilead Sciences Inc. announced Monday it has entered into a definitive agreement to acquire Ouro Medicines, a privately held biotechnology company focused on developing T cell engager therapies for autoimmune diseases.
MSFT
Melius analyst: Microsoft’s Copilot reorganization is a ‘red flag’
Microsoft (NASDAQ:MSFT) is down more than 20% year-to-date, making it the worst-performing stock in the Mag-7 by a wide margin. And according to Ben Wright of Melius Research, who recently cut his price target on the stock, the core problem has a name: Copilot. Wright’s red flag isn’t just about weak adoption numbers. It’s about ... Melius analyst: Microsoft’s Copilot reorganization is a ‘red flag’
AAPL
Melius analyst: Microsoft’s Copilot reorganization is a ‘red flag’
Microsoft (NASDAQ:MSFT) is down more than 20% year-to-date, making it the worst-performing stock in the Mag-7 by a wide margin. And according to Ben Wright of Melius Research, who recently cut his price target on the stock, the core problem has a name: Copilot. Wright’s red flag isn’t just about weak adoption numbers. It’s about ... Melius analyst: Microsoft’s Copilot reorganization is a ‘red flag’
NVDA
Where Could Palantir Be in 3 Years? Here's the Bull Case.
Palantir could become the Microsoft of AI.
INTC
Where Could Palantir Be in 3 Years? Here's the Bull Case.
Palantir could become the Microsoft of AI.